GBI
Research, the leading business intelligence provider, has released its latest
research, "NSCLC Therapeutics in Asia-Pacific Markets to 2019 -
Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to
Expand Treatment Pool", which provides in-depth insights into the
Non-Small Cell Lung Cancer (NSCLC) indication.
The report
provides an estimation of the market size for 2012 along with market forecasts
until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India
and Japan. It also covers disease epidemiology, treatment algorithms, treatment
patterns, clinical trial analysis (including failure rates), pipeline analysis,
and analysis of deals relevant to NSCLC.
View Full Report with TOC @ http://www.radiantinsights.com/research/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool
The NSCLC
market in the APAC region is estimated to have been worth $1.8 billion in 2012
and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to
reach $2.9 billion by 2019. The key drivers for this growth include an aging
population, an increasing number of NSCLC incident cases and the expected
launch of promising therapies.
The launch
of premium-priced novel antibodies and immunotherapies in the first and second
lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's
necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer's
dacomitinib and Novartis's LDK378 are set to drive the market during the
forecast period. However, the recent implementation of a price ceiling on
essential drugs,dominance of generic drugs in India and expected pricing
restrictions in China could curtail the NSCLC market in APAC countries.
Scope
The report
analyzes treatment usage patterns, market characterization, pipeline analysis
and key licensing and co-development deals in Australia, China, India and
Japan. It includes -
- A brief
introduction to NSCLC, including the disease's pathogenesis, etiology, diagnosis
and treatment algorithms
- In-depth
analysis of currently marketed drugs for NSCLC, including analysis of their
safety, efficacy, treatment patterns and strengths and weaknesses, as well as a
heat map comparing them in terms of safety and efficacy
- A
comprehensive review of the pipeline for NSCLC, including individual analysis
of a number of late-stage pipeline drugs likely to enter the market during the
forecast period, analyzed on the basis of phase distribution, molecule type,
program type, mechanisms of action and molecular target
- Additional
in-depth analysis of pipeline drug clinical trials, by Phase, trial size, trial
duration and program failure rate, for each molecule type
-
Multi-scenario forecast data of the market to 2019, taking into account how the
market may be affected by the introduction of new drugs, the expiry of key
patents on current drugs and the changes in disease epidemiology across the key
developed markets
- Discussion
of the drivers of and barriers to market growth
- In-depth
analysis of all licensing and co-development deals that have occurred in the
NSCLC market since 2006
Reasons to buy
The report
will enhance your decision-making capability by allowing you to -
- Understand
the NSCLC pipeline and the factors that indicate that it is becoming more
innovative
- Observe
detailed profiles for promising pipeline products and gain insights into how
they are likely to compete in the market and who their main competitors will be
- Follow the
trends in NSCLC clinical trial size and duration in relation to industry
averages
- Assess the
potential risk of future developmental programs for NSCLC therapeutics,
depending on the mechanism of action, by considering the recorded clinical
trial failure rates
- Observe
the potential growth patterns expected for the NSCLC market over the forecast
period
- Identify
which countries are expected to contribute the most to this growth and devise a
more effectively tailored country strategy through the understanding of key
drivers and barriers in the NSCLC market
- Accelerate
and strengthen your market position by identifying key companies for strategic
partnerships
About Us
Radiant Insights is a platform for companies
looking to meet their market research and business intelligence requirements.
We assist and facilitate organizations and individuals procure market research
reports, helping them in the decision making process. We have a comprehensive
collection of reports, covering over 40 key industries and a host of micro
markets. In addition to over extensive database of reports, our experienced
research coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment